SMU-L11-R
SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8+T cells. SMU-L11-R shows potential in colorectal cancer studies.
For research use only. We do not sell to patients.
- CAS No.: 3040320-18-8
- Formula: C19H24N4O
- Molecular Weight:324.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
human TLR7 0.024 μM (EC50) |
TLR8 2.56 μM (EC50) |
In Vitro
SMU-L11-R (0-100 μM; 24 h; HEK-Blue hTLR7 cells) shows no obvious toxic effect[1].
SMU-L11-R (0-100 μM; 24 h; MC38 and B16-F10 cells) shows cytotoxic in MC38 and B16-F10 cells at a high testing concentration (100 μM)[1].
SMU-L11-R (0, 0.1, 1, 5, 10 μM; 24 h; Peritoneal macrophages) shows dose-dependent increase in M1-like macrophages[1][1].
SMU-L11-R (1 μM; 15-120 min; BMDCs) can activate TLR7 downstream signaling pathways through MyD88 protein, including the NF-κB, MAPK signaling pathways[1].
SMU-L11-R (0, 0.01, 0.1, 1, 10 μM; 24 h; HEK-Blue hTLR7 cells) shows dose-dependent increase in TLR7 protein[1].
SMU-L11-R (0-10 μM; 24 h; Raw 264.7 cells) shows significant increase in TNF-α and IL-6[1].
SMU-L11-R (0-10 μM; 24 h; human PBMCs) shows dose-dependent increase in TNF-α and IL-1β[1].
SMU-L11-R (0-10 μM; 24 h; mouse BMDCs) shows significant increase in IL-6[1].
SMU-L11-R (0, 0.1, 1, 10 μM; 24 h; peritoneal macrophages) shows concentration-dependent increase in NO production[1].
SMU-L11-R also shows the activation of TLR8 (EC50 = 2.56 μM) with the increase of concentration, but the activation was 156 times smaller than that of TLR7. SMU-L11-R induces activation of HEK-Blue hTLR2, hTLR3 or hTLR4 was negligible[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK-Blue hTLR7 cells
-
Concentration:0.26 μM, 0.52 μM, 1.04 μM, 2.08 μM, 4.17 μM, 8.33 μM, 16.67 μM, 33.33 μM, 100 μM
-
Incubation Time:24 h
-
Result:Showed no obvious toxic effect.
-
Cell Line:MC38 cells
-
Concentration:0.02 μM, 0.05 μM, 0.14 μM, 1.23 μM, 11.11 μM, 33.33 μM, 100 μM
-
Incubation Time:24 h
-
Result:Showed cytotoxic effect at a high testing concentration (100 μM).
-
Cell Line:B16-F10 cells
-
Concentration:0.26 μM, 0.52 μM, 1.04 μM, 2.08 μM, 4.17 μM, 8.33 μM, 16.67 μM, 33.33 μM, 100 μM
-
Incubation Time:24 h
-
Result:Showed cytotoxic effect at a high testing concentration (100 μM).
-
Cell Line:HEK-Blue hTLR7 cells
-
Concentration:0, 0.01, 0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Showed dose-dependent increase in TLR7 protein.
-
Cell Line:BMDCs
-
Concentration:1 μM
-
Incubation Time:15 min, 30 min, 60 min, 90 min, 120 min
-
Result:Showed significant induction of the phosphorylation of IKK α/ β, p65, p38 and ERK1/2 in BMDCs.
-
Cell Line:Raw 264.7 cells
-
Concentration:0, 0.01, 0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Showed significant increase in TNF-α and IL-6.
-
Cell Line:Mouse BMDCs
-
Concentration:0, 0.01, 0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Showed significant increase in IL-6.
-
Cell Line:Human PBMCs
-
Concentration:0, 0.01, 0.1, 1, 10 μM
-
Incubation Time:24 h
-
Result:Showed dose-dependent increase in TNF-α and IL-1β.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57/BL6 wild-type male mice (6-8 weeks old) were injected subcutaneousely with 2 x 105 MC38 cells[1]
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:IP; every 2 days; 15 days
-
Result:Significantly inhibited tumor growth and exhibited excellent synergistic anti-tumor effects when combined with PD-L1 inhibitors by upregulating CD8+ T cells.
Chemical Information
-
CAS No. 3040320-18-8
-
Molecular Weight 324.42
-
Formula C19H24N4O
-
SMILES
NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3C[C@@H]4COCC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
PBMC Thawing for Immune Assays
PBMC thawing for immune assays recovers viable cryopreserved peripheral blood mononuclear cells for downstream functional or phenotypic readouts, including ELISPOT, intracellular cytokine staining, proliferation assays, and flow-cytometric immunophenotyping. Cryopreserved PBMCs can support immune monitoring because antigen-specific T-cell function and major CD4/CD8 phenotypes may be retained after optimized freezing and thawing, although some lymphocyte subsets and activation or memory markers can be altered by cryopreservation. The technical objective is rapid warming of the frozen vial followed by controlled dilution and removal of DMSO-containing cryomedium, because thawing and wash conditions measurably affect viable PBMC recovery and downstream assay performance. Viability alone is insufficient for protocol evaluation because high viability may occur with low live-cell recovery, so both viable percentage and absolute live-cell recovery should be measured after thawing.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)